The World’s Top 2% Scientists List is Out!

The World’s Top 2% Scientists List is Out!

Recently, Professor John P.A. Ioannidis and his team from Stanford University, in collaboration with Elsevier, have released the World's Top 2% Scientists list. This list primarily focuses on the "Career-long Impact" which measures the scientific influence throughout an academic career, as well as the "Single-year Impact" which highlights annual scientific achievements. Based on in-depth analysis of data from Scopus and utilizing six comprehensive metrics including citations (differentiating self-citations and others' citations), the H-index, and the HM factor (composite score, C-score), a total of 217,098 scientists have been selected. Among them, 10,687 scientists from mainland China have been included, accounting for 4.92%.
ASH 2024 | Dr. Minghui Duan: Exploring the Combination of Selinexor and Ruxolitinib in Myelofibrosis Treatment

ASH 2024 | Dr. Minghui Duan: Exploring the Combination of Selinexor and Ruxolitinib in Myelofibrosis Treatment

From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, bringing together global experts to discuss the latest advancements in hematology. During this prestigious event, Dr. Minghui Duan from Peking Union Medical College Hospital presented his team’s latest findings on myelofibrosis (MF) treatment (Abstract #1002), offering new perspectives for future therapeutic strategies. To provide deeper insights, Hematology Frontier invited Professor Duan for an in-depth discussion on his research.
ASH 2024 | Professor Jerald Radich：Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins

ASH 2024 | Professor Jerald Radich：Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins

Minimal residual disease (MRD) is a powerful predictor of relapse in acute myeloid leukemia (AML), yet its accuracy remains a challenge. Some patients who are MRD-positive do not relapse, while others who are MRD-negative still experience disease recurrence. At the 2024 American Society of Hematology (ASH) Annual Meeting, Professor Jerald Radich from Fred Hutchinson Cancer Center provided an in-depth analysis of how mutations, clonal architecture, and disease evolution influence treatment response, resistance, and relapse.To clarify the complex relationship between MRD and clonal dynamics, Hematology Frontier has compiled key insights from this discussion.